Background Most adults with major depressive disorder (MDD) fail to achieve remission with
index pharmacological treatment. Moreover, at least half will not achieve and sustain …

Studies have found that up to two-thirds of patients with major depressive disorder (MDD) do
not fully respond to the first antidepressant. While switching antidepressants is a common …

Objective: Treatment-resistant depression (TRD) represents a considerable global health
concern. The goal of the InSight study was to investigate the prevalence of TRD and to …

Purpose Anhedonia is a core symptom of major depressive disorder (MDD), which has
important functional consequences for the patient. This post hoc analysis investigated the …

Response to treatment with selective serotonin reuptake inhibitors (SSRIs) varies
considerably between patients. The International SSRI Pharmacogenomics Consortium …

Major depressive disorder (MDD) is associated with circadian rhythm disruption. Yet, no
circadian rhythm biomarkers have been clinically validated for assessing antidepressant …

Major depressive disorder (MDD) is a prevalent mental health condition and has become a
pressing societal challenge. Early prediction of treatment response may aid in the …

The identification of generalizable treatment response classes (TRC [s]) in major depressive
disorder (MDD) would facilitate comparisons across studies and the development of …

Treating to target in chronic diseases [eg Major Depressive Disorder (MDD)] fosters
precision, consistency, and appropriateness of treatment selection and sequencing …

Discovering that the anesthetic drug ketamine has rapidly acting antidepressant effects in
many individuals with major depression is one of the most important findings in clinical …